Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial to Determine the Safety, Tolerability, and Efficacy of A6, a CD44 Binding Peptide, for the Treatment of Patients With Chronic Lymphocytic Leukemia

NCT02046928 is registered in ClinicalTrials.gov with Ångstrom Pharmaceuticals as lead sponsor.

NCT NCT02046928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02046928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial to Determine the Safety, Tolerability, and Efficacy of A6, a CD44 Binding Peptide, for the Treatment of Patients With Chronic Lymphocytic Leukemia
Lead sponsor
Ångstrom Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2014
Completion date
March 31, 2016
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, cll, sll, small lymphocytic lymphoma